If you have some funds to invest into the Australian share market in October, then I think it could be worth splitting them across the two ASX shares listed below.
Here’s why I think they would be great options this month:
CSL Limited (ASX: CSL)
I think this biotherapeutics giant’s shares are trading at a very attractive level following a 17% pullback from their 52-week high. This pullback has been caused by concerns over its performance in FY 2021 due to difficulties collecting plasma during the pandemic. These collections are vital for CSL because plasma is used to create some of its leading therapies. A shortage could drive prices higher and lead to margin compression.
While I suspect that this will weigh on its performance slightly, I’m optimistic that increasing demand for seasonal flu vaccines will help offset this. Furthermore, it is worth remembering that this headwind is only temporary and trading conditions will return to normal once the pandemic passes. In light of this, I feel investors should be focusing on its future, which is looking very positive. This is thanks to its leading therapies, recent acquisitions, and its high level of investment in research and development.
Xero Limited (ASX: XRO)
Another ASX 200 share I would buy is Xero. It is a leading global provider of cloud-based business and accounting software. I believe Xero would be a great option for investors due to its exceptionally positive long term outlook thanks to the ongoing shift to cloud-based solutions.
This shift is underpinning strong demand for its high quality and sticky platform, which is generating growing recurring revenues. Positively, while the pandemic has hit small and medium sized businesses hard, it hasn’t prevented Xero from continuing its growth in FY 2021. From between April and through to 31 July, Xero added 96,000 net subscribers to its platform. This lifted its subscribers to a total of 2.38 million at the end of the period. While this is a large number, it is still only a fraction of its global addressable market.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- 5 things to watch on the ASX 200 next week
- Where to invest $10,000 into ASX shares next week
- I would buy CSL (ASX:CSL) and this outstanding ASX blue chip share
- ASX 200 down 0.95%: Mesoblast crashes lower on FDA update, Afterpay surges higher
- Why WAAAX shares like Afterpay (ASX:APT) and Xero (ASX:XRO) are surging
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and Xero. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post 2 of the best ASX 200 shares to buy in October appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3juANv4
Leave a Reply